Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate ... - WELT ONLINE PDF Print
WELT ONLINESeattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and ...Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.